By some accounts, about 39%-82% of people who have been diagnosed with a Pseudomonas aeruginosa infection will recover. It's extremely hard for people with cystic fibrosis to beat the infection ...

an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas ...

BIOC-11 is under development for the treatment of bronchiectasis caused by Pseudomonas aeruginosa and cystic fibrosis. This candidate is formulated as an isotonic, buffered aqueous solution for oral ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...